RapidInformationonOLMNo6.docVIP

PAGE  PAGE 7 Rapid Information on Olmesartan and other ARBs No.205 2014/01/06 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 205-1：Treatment with olmesartan effectively attenuated cognitive impairment and BBB disruption as well as renal injury in salt-treated type 2 diabetic mice. Co-administration of suppressive dose of the CCB, azelnidipine significantly exaggerated the protective effects of olmesartan. 2-3 Title：Calcium Channel Blocker Enhances Beneficial Effects of an Angiotensin II AT1 Receptor Blocker against Cerebrovascular-Renal Injury in type 2 Diabetic Mice. 205-2: Extensive clinical evidence has demonstrated the excellent efficacy and tolerability profile of olmesartan including in elderly patients.　(Review)　　　4 Title：Olmesartan in the treatment of hypertension in elderly patients: a review of the primary evidence. 205-3: Olmesartan, captopril, melatonin and C21 exerted a similar level of renoprotective effects in doxorubicin-induced nephrotoxicity in rats.　　　　5-6 Title：Protective effect of captopril, olmesartan, melatonin and compound 21 on doxorubicin-induced nephrotoxicity in rats. 205-4：The combination of rosuvastatin with telmisartan increased the possibly antiatherosclerotic HDL-Lp-PLA2 activity, but not with olmesartan.　　　　　6 Title：Combining Rosuvastatin With Angiotensin-Receptor Blockers of Different PPARγ-Activating Capacity: Effects on High-Density Lipoprotein Subfractions and Associated Enzymes. Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, CKD: chronic kidney disease, T2DM: type 2 diabetes mellitus, HR: hazard ratio, OR: odds ratio, 205-1：Treatment with olmesartan effectively attenuated cognitive impairment and BBB disruption a